Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,064 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $51,306.08. Following the transaction, the senior vice president now owns 4,232 shares in the company, valued at $204,067.04. This trade represents a 20.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $50.21 on Wednesday. The company has a 50-day simple moving average of $44.39 and a 200 day simple moving average of $42.02. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $50.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the business posted ($0.57) EPS. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Mirum Pharmaceuticals by 8.4% in the fourth quarter. Bank of New York Mellon Corp now owns 124,328 shares of the company’s stock valued at $5,141,000 after buying an additional 9,629 shares during the period. Rhumbline Advisers raised its position in Mirum Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after acquiring an additional 1,236 shares in the last quarter. Legato Capital Management LLC lifted its holdings in Mirum Pharmaceuticals by 7.9% in the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after acquiring an additional 977 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $413,000. Finally, Empowered Funds LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $1,376,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MIRM. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners upped their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.